Neuroscience latest news

Neuroscience

Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology

January 23, 2025
United States
Neuroscience

SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression

January 21, 2025
United States
Neuroscience

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

January 13, 2025
Neuroscience

Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis

January 9, 2025
United States
Neuroscience

Johnson & Johnson’s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer’s Disease

January 8, 2025
United States
Neuroscience

Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress

October 24, 2024
Neuroscience

Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study

October 15, 2024
United States
Neuroscience

Johnson & Johnson showcases innovation and commitment to people living with gMG, presenting 25 abstracts at AANEM Annual Meeting and MGFA Scientific Session

October 3, 2024
United States
Neuroscience

Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of Medicine

August 7, 2024
United States
Neuroscience

Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression

July 22, 2024
United States